Are #ViralVectors a key path fwd for #AgingReversal & #ExtremeLongevity #GeneticDrugTherapies & how can a #RealisticVirtualEarth #ForPharmacology https://t.co/8Kx5cOWGm5 help scale access to potential #GeneDrugTherapies & #ViralGeneDrugTherapies ahead -https://t.co/oVza9EO3yb ?
— WorldUnivandSch (@WorldUnivAndSch) June 19, 2025

https://x.com/WorldUnivAndSch/status/1935772245336678889

https://x.com/Q_YogaMacFlower/status/1935772542519963775

https://x.com/scottmacleod/status/1935772762695778527

https://x.com/HarbinBook/status/1935773991119339962

http://x.com/WUaSPress/status/1935773391757426837

https://x.com/sgkmacleod/status/1935773220311040233

https://x.com/TheOpenBand/status/1935774386952585551

* *

Tech News Th June 14 2025 - genetics & viral vectors especially

64x Bio Unveils AAV Apex Suite to Address Gene Therapy Manufacturing Bottlenecks

64x Bio launches AAV Apex Suite, a high-yield manufacturing platform powered by VectorSelect, to tackle the cost and scalability challenges limiting gene therapy’s potential.

June 16, 2025

https://x.com/geochurch/status/1935723459734090207

https://www.synbiobeta.com/read/64x-bio-unveils-aav-apex-suite-to-address-gene-therapy-manufacturing-bottlenecks

64x Bio, a biotechnology company focused on scalable solutions for advanced therapy production, has officially launched AAV Apex Suite, a high-performance product line aimed at solving one of gene therapy’s most pressing issues: manufacturing constraints. The launch follows the formation of strategic collaborations with five leading global biopharma and CDMO partners, underscoring industry demand for improved viral vector production.

Gene therapies hold transformative potential, but their reach has been limited by high manufacturing costs and low scalability. AAV Apex Suite tackles this challenge head-on, offering suspension-adapted HEK293 cell lines optimized for transient transfection and delivering titers exceeding E15 vg/L. These results have been independently validated across various serotypes and therapeutic payloads, consistently achieving high yield and quality.

"The grand challenges for gene therapies have shifted from target organ specificity and how to fit large genes into small capsids to the challenge of low-cost, high-quality manufacturing of AAV therapies. So it is with great pleasure that we see this milestone from 64x," said George Church, PhD, Co-founder of 64x Bio.

The AAV Apex Suite is powered by 64x Bio’s VectorSelect platform, an advanced system that maps the cellular pathways driving productivity. VectorSelect combines genetic and metabolic profiling to guide both cell line engineering and media formulation. As the platform’s dataset continues to grow, 64x Bio is applying computational tools to refine and accelerate new product development.

“Our goal is to enable gene therapies and next generation medicines to succeed by fixing the cost and scale problems that hold them back,” said Lexi Rovner, PhD, CEO and Co-founder of 64x Bio. “Our team has done incredible work to develop AAV Apex Suite as an initial demonstration of what our platform can achieve. We’re already building on this foundation and continuing to develop more that we’ll be sharing soon,” she added.

The launch of AAV Apex Suite comes at a critical time for gene therapy manufacturing. Five prominent biopharma and CDMO partners have already committed to collaborations, highlighting the urgency to resolve production limitations. While AAV Apex Suite currently supports transient production, 64x Bio is actively developing stable cell lines, with plans to expand the suite further.

Beyond the off-the-shelf capabilities of AAV Apex Suite, the company is also offering custom solutions through its VectorSelect platform. These custom projects extend beyond AAV, as 64x Bio continues to explore applications in broader advanced biologics manufacturing.

To learn more about AAV Apex Suite or discuss partnership opportunities, visit www.64xbio.com.

* *

viral vector production

Viral vector manufacturing is the process of producing viral vectors, which are modified viruses used to deliver genetic material into cells for various applications like gene therapy and vaccine development. The process involves several key steps: vector design, where the therapeutic gene is incorporated; host cell selection and genetic engineering; cell cultivation in bioreactors; virus production; harvesting; purification to remove impurities; quality control to ensure safety and potency; and formulation into a usable product.

Key aspects of viral vector manufacturing:

Vector Design:

Selecting the therapeutic gene and incorporating it into the viral vector's genome, while ensuring the vector is replication-deficient to prevent disease.

Host Cell Selection and Modification:

Choosing suitable host cells (e.g., mammalian cells) and genetically engineering them to produce the desired viral vector.

Cell Cultivation:

Growing the modified host cells in bioreactors under controlled conditions.

Virus Production:

The cells produce the viral vectors during cultivation.

Harvesting and Purification:

Separating the viral vectors from the host cells and purifying them to remove impurities like empty capsids and host cell proteins.

Quality Control:

Rigorous testing to assess the safety, potency, and purity of the final product.

Formulation:

Preparing the purified viral vectors into a stable dosage form for storage and administration.

Challenges in Viral Vector Manufacturing:

Scalability:

Scaling up production from research to commercial levels is a significant challenge.

Cost:

Manufacturing viral vectors, particularly using adherent cell culture, can be expensive.

Purity and Consistency:

Ensuring high purity and consistency of the viral vector product is crucial for safety and efficacy.

Process Development:

Optimizing the upstream and downstream processes is essential for efficient and cost-effective production.

Regulatory Compliance:

Meeting stringent regulatory requirements for viral vector manufacturing is vital.

Types of Viral Vectors:

Retrovirus: Capable of stably integrating into the host genome.

Lentivirus: Can integrate into the genome of non-dividing cells.

Adenovirus: A DNA virus that replicates in the cell nucleus.

Adeno-associated virus (AAV): A small DNA virus that can infect both dividing and non-dividing cells.

Oncolytic viruses: Viruses that selectively kill cancer cells.

Emerging Trends:

Suspension-based systems:

Moving towards suspension cell culture for increased scalability and cost-effectiveness.

Single-use technologies:

Utilizing disposable bioreactors and other components to reduce contamination risks and improve efficiency.

Process analytical technologies (PAT):

Implementing PAT to monitor and control the manufacturing process in real-time.

Advanced purification methods:

Developing more efficient and robust purification techniques to improve product quality

simulations of viral vectors for gene therapy

Simulations of viral vectors for gene therapy involve using computational models to predict and optimize the behavior of these delivery vehicles. These simulations help researchers understand how viral vectors interact with cells and tissues, their potential toxicity, and how to improve their efficacy and safety. By modeling various factors like vector design, cellular environment, and immune response, these simulations guide the development of more effective and targeted gene therapies.

Here's a more detailed look:

What are Viral Vectors?

Prospective approaches to gene therapy computational modeling ...

Viral vectors are essentially modified viruses used to deliver therapeutic genes into cells. They are designed to be safe and efficient delivery systems, replacing the virus's natural disease-causing genes with the desired therapeutic gene.

Why are Simulations Important?

Optimizing Vector Design:
Simulations allow researchers to test different vector designs, such as capsid types (e.g., AAV, lentivirus) and promoters, virtually before moving to costly and time-consuming experiments.
Predicting Immune Response:
Simulations can model how the body's immune system will react to the viral vector, helping to minimize potential adverse reactions.
Targeting Specific Cells and Tissues:
Simulations can help optimize the targeting of viral vectors to specific cell types or tissues, improving the effectiveness of gene therapy.
Assessing Safety:
By simulating various scenarios, researchers can identify potential risks associated with viral vectors and develop strategies to mitigate them, ensuring the safety of gene therapy treatments.
Guiding Clinical Trials:
Computational models can help design more efficient and informative clinical trials by predicting optimal dosages, delivery routes, and patient populations.

Examples of Simulation Applications:

Modeling AAV Vector Trafficking:
.Opens in new tab
Simulating how AAV vectors move through the body, enter cells, and deliver their genetic cargo.
Predicting Immune Responses to Viral Vectors:
.Opens in new tab
Modeling the interactions between viral vectors and the immune system to predict potential immune responses and develop strategies to mitigate them.
Optimizing Vector Design for Specific Diseases:
.Opens in new tab
Tailoring vector design, such as capsid type and promoter selection, to maximize gene expression in the target cells for a specific disease.
Simulating Gene Editing Outcomes:
.Opens in new tab
Modeling the outcomes of CRISPR-based gene editing using viral vectors, including off-target effects.

Types of Simulations:

Molecular Dynamics Simulations:
Simulating the movement and interactions of molecules (e.g., viral capsid proteins, DNA) at the atomic level.
Agent-Based Modeling:
Modeling the behavior of individual cells and vectors as "agents" interacting within a larger system (e.g., a tissue).
Computational Fluid Dynamics:
Simulating the flow of fluids (e.g., blood) and the movement of vectors within the body.

In Conclusion:

Simulations of viral vectors play a crucial role in advancing gene therapy. By providing valuable insights into vector behavior and interactions, they enable researchers to design safer, more effective, and more targeted gene therapies for a wide range of diseases

from same search -

. 2020 Mar 30;17:752–757. doi: 10.1016/j.omtm.2020.03.024

VSeq-Toolkit: Comprehensive Computational Analysis of Viral Vectors in Gene Therapy

Saira Afzal ^1,^∗, Raffaele Fronza ², Manfred Schmidt ^1,²

https://pmc.ncbi.nlm.nih.gov/articles/PMC7177155/#:~:text=Viral%20vector%20characterization%20and%20analysis,/CompMeth/VSeq%2DToolkit.

Scott MacLeod - World University books

Society, Information Technology, and the Global University (2025, forthcoming)

Scottish Small Piping album #2 - Honey Piobaireachd (2022)

- https://twitter.com/TheOpenBand (Berkeley)

- Poetry! Order Book #5 Light, Float, Sit, Watsu ~ Virtually (2021)

Scottish Small Piping album #1 Honey in the Bag ~ Out of the Air tune (2020)

Order Book #4 To the Dance or the Pools? ~ Virtually! How different it is to soak at Harbin Hot Springs, than to realize it in virtual reality (2019)

Order Book #3 Winding Road Rainbow: Harbin, Wandering & the Poetry of Loving Bliss (2018)

Order Book #2 Haiku-ish and Other Loving Hippie Harbin Poetry (2017)

Order Actual-Virtual Ethnographic Book #1: Naked Harbin Ethnography (2016)

- https://twitter.com/HarbinBook

- Scott GK MacLeod

Founder, President, CEO & Professor

CC-4 licensed MIT OCW-centric, Wiki,

World University & School (WUaS)

- USPS US Post Office, General Delivery, Canyon, CA 94516

1) non-profit 501(c)(3) Public Charity

MIT OCW-centric,

wiki https://wiki.worlduniversityandschool.org/wiki/Subjects,

World University and School - http://worlduniversityandschool.org

- https://twitter.com/WorldUnivAndSch

2) for profit general stock company WUaS Corporation in CA - http://worlduniversityandschool.org/AcademicPress.html

- https://twitter.com/WUaSPress

(o) 415 480 4577 - sgkmacleod@worlduniversityandschool.org

(m) 412 478 0116 - sgkmacleod@gmail.com

World Univ & Sch Innovation Research - scottmacleod.com

- https://twitter.com/scottmacleod

- https://x.com/Q_YogaMacFlower/status/1815700381474689273

- http://www.linkedin.com/in/scottgkmacleod

- https://twitter.com/sgkmacleod (all 7,159 known living languages at WUaS)

- https://scott-macleod.blogspot.com/search/label/global%20university

- https://worlduniversityandschool.blogspot.com/search/label/global%20university

* *

Nice to see you & visit Byron! (email thread beginning June 5 2025)

Byron, Drs. all,

How are you? Just drove in from Lake County passing by your house on Larch, Byron, and into the Canyon 94516 USPO. About right when I entered the town of Moraga near the Rheem Valley shopping mall area, Andrea from Kaiser Permanente called me in vehicle and asked if I had received my fit kit for a home feces' sample for colorectal cancer, which I mailed in for years from 670 Ridgecrest Rd Canyon 94516 ... But sadly which fit kit I could not get either 8n safe house north of Berkeley in El Cerrito for 2.4 years or in asylum 8n Pittsburgh for 2.5 years due to the US federal post office not forwarding my or Work World University and Schools' paper maul fir all those years (breaking the law and putting me at risk for colorectal cancer). When I asked at the canyon PO, she said I and World Univ & Sch hadn't gotten any paper mail: I mentioned the KP call and asked if this Canyon PO will be open tomorrow Sat from 730-10 am. The USPO clerk said yes, but she wouldn't be the USPO clerk there tomorrow. She also said she didn't need yo know the spelling if MacLeod or WUaS ... Due to the 30 days' USPS General Delivery Holding period... SO I'll check again for my General delivery mail in Canyon tomorrow (and did the Canyon resident mail deliverer from Rheem to Canyon pull up quasi secretively and park on the other side of the USPO clerk's car while I was there, whom I greeted last time ... And re USPO Canyon's possible 'secrets' )?

And how do the KP AND USPS' AI and ML all interoperate these days as US federal and state of CA IT systems ?

Drs especially :

Genetics' and KP medical test #PacketThroughTheMail Question for you - could scientists get enough genetic material from such a fit kit for colorectal cancer screening to even develop & produce in the future personalized vaccines, eg as possible #ViralVectors or similar, and eventually for #Aging Reversal and #ExtremeLongevity genetic drug therapies as vaccines ? (And See PS and blog post from today too, and I may ask Gemini conversational generative artificial intelligence this as well ).

Thoughts?

Scott

https://scott-macleod.blogspot.com/2025/06/racoon.html

Are #ViralVectors a key path fwd for #AgingReversal & #ExtremeLongevity #GeneticDrugTherapies & how can a #RealisticVirtualEarth #ForPharmacology https://www.toolify.ai/ai-news/revolutionizing-education-with-machine-learning-and-ai-2574306 help scale access to potential #GeneDrugTherapies & #ViralGeneDrugTherapies ahead -
https://scott-macleod.blogspot.com/2025/06/racoon.html ?

https://x.com/WorldUnivAndSch/status/1935772245336678889

https://x.com/Q_YogaMacFlower/status/1935772542519963775

https://x.com/scottmacleod/status/1935772762695778527

https://x.com/HarbinBook/status/1935773991119339962

http://x.com/WUaSPress/status/1935773391757426837

https://x.com/sgkmacleod/status/1935773220311040233

https://x.com/TheOpenBand/status/1935774386952585551

Scott MacLeod sgkmacleod@gmail.com

Jun 21, 2025, 10:35 AM (21 hours ago)

to Peter, Byron, Byron, Ed, Janie, Pin, Donna, George, Annie, Alden, warren

Dear Byron, Ed, Pin/Sid, Peter, George, US Senator and former Harvard Law Professor Elizabeth Warren, All,

Greetings from Moraga and having just checked at the Canyon 94516 US Post Office whether I had gotten any mail USPS general delivery, especially regarding the Kaiser Permanente call to me yesterday F June 20, 2025 saying KP had sent me a Fit Fecal Immunochemical Test) kit. No mail was there for me or for World University and School, the postal clerk said (who was a different USPS clerk from yesterday, but whom I've seen before). I'll check again I think on Monday or Tuesday, and if not will call the Kaiser Permanente number KP's Andrea called me from, and inquire how best to proceed. I did meet Esperanza (Surls), a very long time Canyonite, in front of the Canyon USPO ... and we talked a little about my Sienna ... and as I headed into the USPO, she said "Take it easy;" I'm not sure whether this could refer to my moving WUaS into a newly safe vacant 670 Ridgecrest Road, Canyon 94516 or what ... (and with US federal law working with state of California law in new ways effectively). Thoughts?

I asked Gemini AI:

"Could scientists get enough genetic material from feces in a fit kit from Kaiser Permanente for colorectal cancer screening to even develop and produce in the future personalized vaccines for example as possible viral vectors or similar and eventually for aging reversal and extreme longevity genetic drug therapies as vaccines ?

And received this Great response -

https://g.co/gemini/share/fe226ff99473

Drs. What do you think, especially? And how could a #RealisticVirtualEarthForMedicine help

Heading back to Lake county soon.

Best regards, abolitionally, Yogically, cheers,

Scott